Introduction
Atherosclerosis is one of the most common vascular disorders. Proliferation of vascular smooth muscle cells (VSMCs) and the formation of neointima dominate atherosclerosis lesion development. p53, an essential molecule in cell cycle and apoptosis control, also plays a central role in atherosclerosis [1] [2] [3] . Inactivation of p53 stimulates the development of atherosclerosis [4] [5] [6] . A complex network that includes p300 and Mouse Double Minute 2 (MDM2) regulates p53. p300
is an acetyltransferase which acetylates p53 to enhance its activity [7] [8] [9] . MDM2, an E3 ubiquitinprotein ligase, degrades p53 via the ubiquitin-proteasome pathway 10, 11 . MDM2 also blocks P300 interaction with p53, thereby inhibiting p53 acetylation and decreasing its activity [12] [13] [14] .
Intriguingly, whereas MDM2 is a key regulator of the fate and activity of p53, the transcription of MDM2 itself is under the control of p53, establishing a p53/MDM2 negative feedback loop.
More than 90% of the human genome is transcribed [15] [16] [17] . Whereas protein-coding genes account for less than 2% of the human genome, non-coding RNAs (ncRNAs) are important components of the mammalian transcriptome 18, 19 . There are several classes of ncRNAs, including the well-known microRNAs (miRNAs), which are ~21-23nt long and have been proven to play a key role in the regulation of gene expression and function in a variety of biological and pathological processes [20] [21] [22] [23] . Long non-coding RNAs (lncRNAs), also known as long intergenic non-coding RNAs (lincRNAs), constitute another class of ncRNAs. Defined as non-coding transcripts longer than 200 nucleotides, at least a subset of lncRNAs are likely to have biological activity [24] [25] [26] . Numerous studies have already shown the involvement of lncRNAs in cancer development [27] [28] [29] . However, the role of lncRNAs in cardiovascular system is less understood 30 . A recent study discovered Braveheart (Bvht), a heart-associated murine lncRNA, and demonstrated that Bvht is essential for the maintenance of the fate of cardiomyocytes 31 .
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LincRNA-p21 was initially identified as a direct transcriptional target of p53 33 .
LincRNA-p21 appears to function as a component of the p53 pathway, at least in part, by physically interacting with a p53 repressive complex to downregulate many p53 target genes 33 .
lincRNA-p21 also acts as a suppressor of translation by directly associating with target mRNAs 34 . Despite these studies, the biological function of lincRNA-p21 remains elusive.
In this study, we examined the functional role of lincRNA-p21 in the pathogenesis of atherosclerosis. We showed that the expression level of lincRNA-p21 was lower in atherosclerotic plaques of the ApoE -/-mice. Importantly, we found that inhibition of lincRNAp21 increased cell proliferation and neointima formation in injured carotid arteries. Among the genes dysregulated by lincRNA-p21 inhibition was MDM2. We show that MDM2 interacts with lincRNA-p21 to relieve its repression of p53. Our study therefore uncovered a critical function of lincRNA-p21 in atherosclerosis.
Materials and Methods

Cell culture, transfection, Cellular proliferation and apoptosis analysis
Human vascular smooth muscle cell line HA-VSMC and mouse mononuclear macrophage cell line RAW264.7 were purchased from ATCC and cultured following the instructions of manufacturers. Cells were transfected using Lipofectamine 2000.
Cells were seeded in 96-well plates, and cell proliferation was tested using the Cell Counting Kit-8 (CCK-8) assay Kit. Proliferating HA-VSMCs were quantified by Ki67 staining.
atherosclerosis. We showed that the expression level of lincRNA-p21 was lower r i in n atherosclerotic plaques of the ApoE -/-mice. Importantly, we found that inhibition of lincRNA- For cellular apoptosis assay, HA-VSMCs were seeded in 48-well plates and TUNEL assay was performed using the ApopTag® Plus In Situ Apoptosis Fluorescein Detection Kit.
RNA isolation, qRT-PCR analysis and Unbiased gene expression profiling
Total RNAs were isolated using TRIzol reagent. Reverse transcription (RT) and real time quantitative PCR (qRCR) were performed, following manufacturer's instructions. PCR primers are listed in Supplemental Table 1 . Unbiased genome-wide transcriptome profiling was performed using the HUGENE 2.0 ST array (Affymetrix), which interrogates a total of 40,716
Refseq transcripts. Arrays hybridization, signal detection and data analysis were performed as described 35, 36 .
RNA immunoprecipitation, RIP assay
RNA immunoprecipitation (RIP) experiments were performed using the Magna RIP RNABinding Protein Immunoprecipitation Kit following the manufacturer's instructions. Two independent MDM2 antibodies were used.
Biotin RNA pull-down assay and deletion mapping and bioinformatics
RNA pull-down assay and deletion mapping were performed as described previously 37 . Briefly, the pcDNA3.1-lincRNA-p21 plasmid was used as template to synthesize biotinylated lincRNAp21 transcripts. For biotinylated RNA generation, PCR products were used for in vitro transcription with the Biotin RNA Labeling Mix and T7 RNA polymerase. Nuclear proteins were extracted using Nuclear and Cytoplasmic Protein Extraction Kit. After incubation, binding and washing, beads were boiled in SDS buffer, and retrieved protein was detected by standard western blotting.
CatRAPID 38 and RPIseq 39 , online protein-RNA binding predictors, were used to test the potential binding of MDM2 to lincRNA-p21.
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Chromatin immunoprecipitation and ChIP-Seq assays
Injury-induced mouse model of carotid artery neointimal hyperplasia
Local lentivirus-mediated gene transfer into injured carotid arteries was performed as described previously 42, 43 . Briefly, C57BL/6J mice underwent metal wire injury of the common carotid artery (N=5 for each group). After local injury and heparin injection, 20ul of recombinant lentivirus Si-mlincRNA-p21 (1×10 8 UT/ml) and cntl-SiRNA(1×10 8 UT/ml) were instilled into the common carotid artery and allowed to dwell for 30 minutes. Uninjured arteries were used as sham control.
For cell proliferation and apoptosis, immunofluorescence and TUNEL assays, respectively, were performed. Sections were incubated with antibodies against Ki67. Terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) assays were performed on paraffin sections using the ApopTag® Plus In Situ Apoptosis Fluorescein Detection Kit 
Clinical inclusion criteria
The coronary artery disease (CAD) group contained patients with greater than 80% coronary artery stenosis and the control group contained patients without clinically significant coronary artery occlusion were recruited. All procedures were conducted in compliance protocols approved by the Third Military Medical University Ethics Committee, and written informed consent was received from all participants. Details of all probands are presented in Supplemental Tables 2 and 3 .
Statistical analysis
All data are expressed as mean ± SD unless otherwise stated. Data from each experiment were individually analyzed and statistics applied. We used Student's unpaired t-test to compare 2 independent groups. In experiments comparing multiple time points, separate t-tests were used 
Results
LincRNA-p21 regulates cell proliferation and apoptosis
Given the vital role of p53 in the pathogenesis of atherosclerosis and the recent report that p53 regulates the expression of lincRNA-p21 33 , we hypothesized that lincRNA-p21 is also involved in the development of atherosclerosis. We first examined the expression of lincRNA-p21 in aortic atherosclerotic plaques of ApoE -/-mice fed a high-fat diet, a widely used animal model of All data are expressed as mean ± SD unless otherwise stated. Data from each exp xp per rim im i en ent t t we we were re ndividually analyzed and statistics applied. We used Student's unpaired t-test to compare 2 n nde de epe pe pend nd nden en ent t t g g grou ou up ps ps. In experiments comparing m m mu ul ltiple time poin in nts, se se ep pa parate t-tests were used f fo or ea e ch time po poin int t. atherosclerosis. Indeed, we found that the expression of lincRNA-p21 was substantially lower in the aortic plaques of ApoE -/-mice when compared with that of wild type control mice,
suggesting that lincRNA-p21 may play a role in atherosclerosis ( Figure 1A) .
Next, we investigated the function of lincRNA-p21 in cell proliferation and apoptosis.
We used the mouse macrophage cell line RAW264.7 and the human vascular smooth muscle cell line HA-VSMC, both of which have been widely used to study atherosclerosis in vitro. We designed small interfering RNA (siRNA) to inhibit mouse lincRNA-p21 (mlincRNA-p21) and human lincRNA-p21 (hlincRNA-p21) expression. The efficiency of siRNA transfection and the inhibition of endogenous lincRNA-p21 were tested and confirmed by qRT-PCR ( Figure 1B) .
Inhibition of lincRNA-p21 substantially increased total cell numbers in both RAW264.7 and HA-VSMC cells ( Figure 1C ). Increased cell proliferation and viability in these cells were further confirmed using an independent sensitive colorimetric assay ( Figure 1D ). Furthermore, lincRNA-p21 knockdown decreased apoptosis in both cell lines (Figures 1E and 1F) . Together, these data indicate that lincRNA-p21 suppresses cell proliferation and induces apoptosis.
LincRNA-p21 regulates the expression of p53 target genes
In order to understand the molecular mechanism by which linRNA-p21 regulates cell proliferation and apoptosis, we performed unbiased gene array analysis to measure gene expression changes in lincRNA-p21 knockdown cells. We found that 331 and 274 genes were up-and down-regulated more than two folds, respectively, when linRNA-p21 was knocked down 
LincRNA-p21 interacts with MDM2
The above results indicated that lincRNA-p21 participates in the regulation of p53-dependent target gene expression without altering the expression level of p53 itself, suggesting that lincRNA-p21 might instead modulate the transcriptional activity of p53. Previous work showed that p300 and MDM2 play important roles in the regulation of p53 activity. P300 is an acetyltransferase which acetylates p53 and thereby enhance its activity. MDM2 antagonizes p53
by enhancing its degradation via the ubiquitin-proteasome pathway and by blocking its binding and acetylation by p300 [7] [8] [9] .
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LincRNA-p21 regulates the transcriptional activity of p53
To understand how the lincRNA-p21/MDM2 interaction affects the formation of the p53/p300/MDM2 complex, co-immunoprecipitation (Co-IP) experiments were performed. We confirmed the interaction of p300 and p53, and MDM2 and p53, consistent with prior reports [12] [13] [14] .
As expected, the interaction of p300/p53 and MDM2/p53 increased in p53 overexpressing cells.
LincRNA-p21 knockdown decreased p300/p53 interaction and increased MDM2/p53 interaction.
In contrast, no interaction was detected when IgG was used for IP, demonstrating the specificity of the co-immunoprecipitation interaction assays ( Figure 4A ).
We next investigated if inhibition of lincRNA-p21, which affected interactions between p300, MDM2, and p53 proteins without altering p53 protein level, influenced p53 binding to the promoters/enhancers of its target genes. We performed p53 chromatin immunoprecipitation (ChIP) followed by high-throughput DNA sequencing (ChIP-Seq) experiments in HA-VSMCs treated with control or lincRNA-p21 siRNA. We obtained 36-53 million sequence reads from Figure 3D ).
lincRNA-p21/MDM2 in To o u u und nd nde er erst st stan an a d d d ho o ow w w th t e te e era r r c c ction affects th he e e form rm ma at ation of the p53 3/ /p3 p 00/MDM DM2 2 2 c co com m mple le lex x, , c c co-o--im immu mu muno no op pr r eci ip pi it tatio o on n (C C Co-o--IP IP) ) ) e ex expe pe eri im ment nts we we ere re re p per erfo fo f rm rm r ed ed e . . We We We co onf nf n ir ir irme me m d d th th the e in int t ter ra ract cti ion n n of o p p p30 30 00 0 0 an an and d p p5 p53, 3 3, a a and nd nd MD MD MDM2 M2 M2 a and nd nd p p p53 53 53, c co cons ns nsis ist t ten nt nt w w wit it i h h h pr pr prio io ior r r re e epo po ort rts s each experimental sample, and greater than 95% of them uniquely aligned to the human genome (Supplemental Figure 1) . In control siRNA-treated samples, we identified more than 4,800 p53-bound regions. Intriguingly, lincRNA-p21 knockdown diminished p53 binding at many of these regions ( Figure 4B ), suggesting that lincRNA-p21 is required for p53 to bind to many of its targets. We compared the peak distributions of Mdm2, Puma, Bax and Noxa, four known p53-regulated genes, in control and lincRNA-p21 knockdown cells and found that knockdown of lincRNA-p21 dramatically reduced the association of p53 to the promoters/enhancers of these genes ( Figure 4C) . Similarly, we observed that lincRNA-P21 knockdown diminished the binding of p53 to promoters/enhancers of many additional targets ( Figure 4D ). ChIP-PCR assays further confirmed the above observation ( Figure 4E ). To verify that lincRNA-p21
functionally regulates p53 recruitment to target regulatory regions, we overexpressed p53 with or without knocking down endogenous lincRNA-p21 and measured the binding of p53 to the regulatory regions of target genes. ChIP results showed that p53 recruitment to its target promoters/enhancers was diminished when lincRNA-p21 was knocked down ( Figure 4F ). These observations suggest that lincRNA-p21, a transcriptional target of p53, can feed back and regulate the activity of p53, at least in part, by modulating the interaction of p53, p300 and MDM2.
LincRNA-p21 modulates the function of p53 in regulating cell proliferation and apoptosis
To investigate the interplay of p53 and lincRNA-p21 on cell proliferation, apoptosis and atherosclerosis, we overexpressed p53 in human VSMC cells, with or without lincRNA-p21
knockdown. Whereas overexpression of p53 induced the expression of endogenous lincRNAp21, lincRNA-p21 knockdown had no effect on p53 expression, consistent with the prior observations 33 ( Figure 5A ). Overexpression of p53 inhibited VSMC proliferation and viability, assays further confirmed the above observation ( Figure 4E ). To verify that lincR R R A NA NA-p p21 21 21 functionally regulates p53 recruitment to target regulatory regions, we overexpressed p53 with or wi with th hou ou ut t t kn kn knoc o o k king ng g d d do own endogenous lincRNA-p p2 2 21 a and measured d th t t e bi bi bin nd nding of p53 to the e egu u ula l tory reg gio ion ns ns o of f f t ta t r rg rget et et g g ge en enes es. . C Ch ChI IP IP resu u ult t ts sh h ho ow wed ed d t tha ha at p p5 p53 3 re e ecr crui ui uitm m men en nt t t t to to i its ts ts t tar ar a g get t pr prom om omot ot oter ers/ s/ /en en enha han n nce er ers s wa wa was s di d m mi mini ni nish sh shed ed e w w whe he hen n n l linc nc ncRN RN NA A A-p2 p2 p21 1 1 w wa was s s kn kn noc oc cke ke k
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modulates p53-dependent cell proliferation ( Figure 5B) . Similarly, p53-induced apoptosis was markedly repressed in lincRNA-p21 knockdown cells ( Figure 5C ). Moreover, lincRNA-p21
inhibited the stimulatory effect of p53 overexpression on levels of Mdm2, Puma, Bax and Noxa (Figures 5D and 5E ). Together, these results demonstrate that lincRNA-p21 functions through the p53 pathway to regulate cell proliferation and apoptosis.
It is well established that p53 regulates cell proliferation and apoptosis in response to stress 48 . We tested whether the functional involvement of lincRNA-p21 and p53 in cell proliferation is regulated by treatment of doxorubicin (Dox), an anti-cancer chemotherapy drug which also causes cardiotoxicity 49 . Knockdown lincRNA-p21 increased whereas Dox treatment reduced cell number in culture ( Figures 6A and 6B) , consistent with previous observation. SilincRNA-p21 partially suppressed the Dox-induced reduction of cell number ( Figure 6B ). We further examined apoptosis and cell proliferation under such conditions. We found that Dox treatment significantly induces apoptosis, marked by increased TUNEL staining, which is partially suppressed when lincRAN-p21 was knocked down (Supplemental Figure 2A) .
Conversely, Dox treatment reduced cell proliferation, evidenced by decreased Ki67 labeling.
Knockdown of lincRNA-p21 restored Dox-inhibited cell proliferation (Supplemental Figure   2B ). Next, we examined the expression of p53 target genes in cells treated with Dox and silincRNA-p21. We found that whereas Dox treatment increased the expression of p53 target genes, knocking down endogenous lincRNA-p21 partially suppresses such increase of gene expression ( Figure 6C ).
We asked whether knockdown of lincRNA-p21 might affect p53 protein level and its proliferation is regulated by treatment of doxorubicin (Dox), an anti-cancer chem m moth th her r rap ap apy y y dr dr drug ug which also causes cardiotoxicity acetylation status under stress condition. We found that Dox treatment induced the level of acetylated p53 significantly, which was reduced when endogenous lincRNA-p21 was inhibited ( Figure 6D) . Next, we investigated whether Dox treatment and lincRNA-p21 knockdown could alter the binding of p53 to the promoters/enhancers of its target genes. ChIP-PCR showed that Dox enhances the binding of p53 to its targets, which was reduced when lincRNA-p21 was knocked down (Figure 6E) . In contrast, we found that Dox treatment and lincRNA-p21 knockdown did not affect the expression level of p300 proteins (Figure 6F) , neither did such treatment alter p300 binding to p53 target genes ( Figure 6G) . Together, these studies suggest that linRNA-p21 modulates the activities and functions of p53 in regulating its target gene expression in response to stresses.
LincRNA-p21 inhibits neointima formation in carotid arteries
Next, we investigated the involvement of lincRNA-p21 in the formation of neointima in vivo, using the classic murine carotid artery injury model 50 . Recombinant lentivirus vector expressing lincRNA-p21 siRNA or control siRNA was injected into the injured area of mouse carotid arteries. These mice were then fed with high fat diet for one month, and neointima formation was examined. We verified the reduction of lincRNA-p21 expression in local-injury carotid tissues after lentivirus-si-lincRNA-p21 injection (Supplemental Figure 3) . Knockdown of lincRNAp21 resulted in dramatic neointimal hypertplasia when compared with controls ( Figure 7A ).
Quantification of intima-media thickness confirmed a significant increase after siRNA-lincRNAp21 injection ( Figure 7B) . We asked whether inhibition of lincRNA-p21 affected cell proliferation and apoptosis in vivo. We performed immunostaining on vessel sections to detect the proliferation marker Ki67. The fraction of Ki67 + cells increased in siRNA-lincRNA-p21 treated vessels (Figures 7C and 7D) . LincRNA-p21 siRNA-treated vessels also showed n response to stresses.
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To further uncover the role of lincRNA-p21 on the interaction of p53-p300-MDM2
proteins in vivo, we examined the effect of lincRNA-p21 knockdown on p300/p53 and MDM2/p53 interactions in carotid tissues. Consistent with in vitro studies, there was a reduced binding of p300 and p53 in si-lincRNA-p21 samples. Conversely, the association of MDM2 and p53 was increased in si-lincRNA-p21 samples ( Figure 8A) . As a result, the expression levels of p53 targets Mdm2, Puma, Bax and Noxa were repressed in si-lincRNA-p21 treated vessels in vivo ( Figure 8B ).
Decreased lincRNA-p21 expression in patients with coronary heart disease
Lastly, to determine whether dysregulated lincRNA-p21 expression is associated with coronary artery disease, we examined the expression of human lincRNA-p21, by quantitative RT-PCR assays, using total RNAs isolated from coronary artery tissues of coronary artery disease patients and artery tissues of control patients. Indeed, expression of lincRNA-p21 was more than 50% lower in coronary artery disease patients compared to control patients ( Figure 8C ). Similarly, we tested lincRNA-p21 level in another set of coronatry artery disease and control patients using total RNAs isloated from peripheral blood mononuclear cells and we found that lincRNA-p21 level was also decreased in coronatry artery disease patients (Supplemental Figure 4) . These results implicate lincRNA-p21 in the development of atherosclosis and coronary artery disease.
Discussion
In this study, we indentified lincRNA-p21 as a key regulator of cell proliferation and apoptosis.
We showed that lincRNA-p21 represses cell proliferation and induces apoptosis in vitro and in Decreased lincRNA-p21 expression in patients with coronary heart disease Lastly, to determine whether dysregulated lincRNA-p21 expression is associated with coronary ar rte te ery ry ry d d di is isea ea ease se e, we we we e ex xamined the expression of hu hu um ma an lincRNA-p2 p2 21, b by y yuantitative RT-PCR assa a ays y , using to tot ta al RN RN NAs As s i i i o so sola la lat te ted d fr fr rom om m c c coro ona a ary a ar art tery y y t t tis issu su ue es es o of f c co coro ron na nary ry a a art rt ter ery y di di dise se s a a ase e e pa pati t t e e ents an nd d d ar ar arte te t ry ry y t t tis is issu sue es s o o of f co con nt ntro rol pa pa p ti ti tien en ents ts ts. . In In nde de dee e ed d d, e e exp xp xpr re res ssio io on n n of of of lin in ncR cR cRNA NA NA-p -p p21 1 1 w was as a m m mor or ore e e th ha an an 5 50% 0% % ower in coron on nar ar ary y y ar ar arte te ery ry ry dis is isea ea ease e e p p pa ati ti tien en nts ts ts c c com om ompa pa pare re ed d d to to to c con on ontr tr trol ol o p p pat at atie ent nt n s s s (F (F (Fig ig igur ur u e e e 8C 8C 8C) ) ). . Si Si S milarly, w we e vivo. Knockdown of endogenerous lincRNA-p21 accelerated neointima formation in injured carotid arteries. Mechanistically, we found that lincRNA-p21 directly binds to MDM2, leading to p53 release from MDM2 and binding to p300, which thereby enhances p53 activity. This finding is significant because it implicates non-coding RNAs in cardiovascular diseases such as atherosclerosis, and suggests that modulation of the activity of non-coding RNAs such as lincRNA-p21 may be a novel therapeutic approach to treat human cardiovascular disease.
It is well-known that p53 plays an important role on the pathogenesis of atherosclerosis [1] [2] [3] [4] [5] [6] . The expression and transcriptional activity of p53 is tightly regulated at multiple levels.
Especially, post-transcriptional regulation by ubiquitination and acetylation are known to be essential for the function of p53 proteins. MDM2, a direct transcriptional target gene of p53, appears to take part in both pathways. On one hand, p53 proteins can be degraded by MDM2 via ubiquitination pathway 10, 11 . On the other hand, p53 is well-known to be acetylated by the acetyltransferase p300, resulting in dramatic induction of p53 activity [7] [8] [9] . Interestingly, this effect is antagonized by p53 interaction with MDM2, which inhibits the formation of the p300-p53 complex. Clearly, this dynamic interaction between p300, MDM2, and p53 critically regulates the activity and function of p53, and positions MDM2 as a core regulator of p53 activity 21, 51, 52 .
A prior study showed that lincRNA-p21, which was identified as a transcriptional target of p53, feeds back to stimulate p53 function through its interaction with the RNA-binding protein hnRNP-K 33 . Our study defines a second, MDM2-dependent mechanism by which lincRNA-p21 regulates p53 activity: lincRNA-p21 directly binds to MDM2, reducing p53-MDM2 interaction and increasing p53-p300 interaction. Consequently, the transcriptional activity of p53 is increased. Therefore, our investigation uncovered a novel mechanism by which p53 and lincRNA-p21 regulate each other's expression and activity in a feedback manner ( Figure 8D) .
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Furthermore, it will be important to determine whether such association is regulated in pathophysiological conditions, in particular the cardiovascular diseases. Are there functional correlations of lincRNA-p21 binding to both MDM2 and hnRNP-k?
Our present study uncovered the involvement of lincRNA-p21 in atherosclerosis, at least in part, by interplaying with p53 in a feedback mechanism. It will be interesting to explore whether lincRNA-p21 can interact with epigenetic factors, like PRC1 and PRC2 to regulate the expression of atherosclerosis-related genes. Furthermore, we speculate that variants of lincRNAp21 may be genetically linked to atherosclerosis. Given the existing of large numbers of lncRNAs and their important biological function, it is not unreasonable to predict that additional novel lncRNAs will be identified and linked to atherosclerosis and cardiovascular disease in the near future.
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William Pu for stimulating discussion and careful reading of the manuscript. n part, by interplaying with p53 in a feedback mechanism. It will be interesting t t to e e exp p plo lo lore re re whether lincRNA-p21 can interact with epigenetic factors, like PRC1 and PRC2 to regulate the ex xpr pr pres es ssi si sion on n o of f f at the he her ro rosclerosis-related genes. Furt t t a h h her r rmore, we spec c cul u at te e e th th that variants of lincRNAp2 21 1 ma m y be gen ene e eti ic cal al lly ly l l l lin in inke ke ked d d to to a a ath th her er s os scler r ros sis. G Gi iven en n t the he e e exi xis st tin n ng g of of f la ar arge ge e n n num umbe be bers rs r o o of f n ncR cR cRNA NA NAs s an an and d d th the e eir r r im im mpo po ort rtan ant t t bi bi iol ol olog og ogic ica a al f f fun un unc ctio io ion, n, , it t is no no ot t t u un unre re reas as son on nab ab a le le e t to o pr pr pred ed dic ict t t th th hat t ad dd ddit iti i ion na nal novel lncRNA NA As s wi wi will ll ll b be e e id i i en en enti ti tifi f ed ed ed a and nd n l l lin in inke ke F F F) ) ) Qu Qu Quan an a t t tif fi ica ca ati t on on on o of f ap ap a o op opto to tos sis is s. A Al All l va va valu lu l es es s a a are e th he he average of at t le le leas as a t t t 3 3 3 bi bi iol ol o og g gic ic ical a a re re repl pl p ic ic icat t tes es e a a and nd nd d d dat at a a a a sh sh how ow wn n n ar ar are e e th th the e e me me mean an an±s ±s ±sta ta tand nd n ar ar ard d d de de devi vi viat a ion (SD). . antibodies (or IgG to serve as a negative control) and associated proteins were detected using p300 and MDM2 antibodies, respectively. 10% of the input cell lysates were loaded as controls. antibodies (or IgG to serve as a negative control) and associated proteins were detected using anti-p300 and MDM2 antibodies, respectively. 10% cell lysate were loaded to serve as controls. an nti i ib bodies (or r I IgG gG g to o s ser rv rve e a as as a a n neg eg ega at ati iv ve e e con n ntr r rol) an n nd a a as ss soc ocia a ate ted d p pr rot otei i eins ns w we er ere e de dete t t ct ct c ed ed ed u u usi sin ng ng an nti ti ti-p3 p3 p300 00 a a and nd n M M MD DM DM2 2 2 a an anti tibo bo odi di ies es es, re r resp sp pec c cti ti tiv ve vely y y. . 10 10 0% % % c ce cell ll ll l l ly y ysat at ate e e we we were re re l lo oa oade ded d d to to o s ser er erve v ve a as s c co cont nt tro rols ls. Biotin RNA pull-down assay and deletion mapping RNA pull-down assay and deletion mapping were performed as described previously 37 .
Briefly, the pcDNA3.1-lincRNA-p21 plasmid was used as template to synthesize biotinylated lincRNA-p21 transcripts. Specific PCR primer sequences were as follows:
Forward PCR primers contained the T7 RNA polymerase promoter sequence The retrieved DNAs were eluted, reverse-crosslinked, purified and analyzed by qPCR.
Primer sequences were listed in Supplementary Table 1 .
ChI P-Seq ChIP-Seq was performed from HA-VSMC following NimbleGen protocols for chromatin immunoprecipitation and amplification with minor modifications. Briefly, 5-6x10 7 cells
were crosslinked with 1% formaldehyde for 10 min at RT. The reaction was stopped using 2.5M glycine at RT for 7 min. Nuclear lysates were sonicated to yield 100-1000 bp DNA fragments (predominantly 200-500 bp) and co-incubated with p53-DO1 antibody at , and regions with enriched signal compared to input were identified using MACS, using the default and suggested threshold of 1E-5
39
.
The peaks for selected loci were visualized using IGV (Broad Institute, MA)
I nj ur y-induced mouse model of carotid ar ter y neointimal hyper plasia
Local lentivirus-mediated gene transfer into injured carotid arteries was performed as described previously 40, 41 . Briefly, recombinant lentivirus vector pGLV-h1-GFP-puro expressing Si-RNA against lincRNA-p21 expression (Si-lincRNA-p21) and scramble control siRNA (Cntl-SiRNA) were constructed. C57BL/6J mice underwent metal wire injury of the common carotid artery (N=5 for each group). After local injury and heparin injection, 20ul of recombinant lentivirus Si-mlincRNA-p21 (1×10 8 UT/ml) and cntlSiRNA(1×10 8 UT/ml) were instilled into the common carotid artery and allowed to dwell for 30 minutes. Uninjured arteries were used as sham control. Mice were killed after 30 days' high fat diet induction and carotid arteries were collected, embedded, sectioned and stained with hematoxylin-eosin (H& E) to measure the degree of neointimal thickening.
The intima-media thickness ratios were calculated.
For cell proliferation and apoptosis, immunofluorescence and TUNEL assays, respectively, were performed. Sections were incubated with antibodies against Ki67
(1:200 dilution) followed by fluorescein conjugated secondary antibodies (1:400 dilution).
Cell Coronary artery tissues from CAD patients and aorta tissues from control group were collected for RNA extraction (Supplemental Table 2 ). Additionally, we recruited a distince cohort of coronary artery disease patients and controls (Supplemental Table 3 ). Total
RNAs were isolated from peripheral blood mononuclear cells of these patients and control groups. All procedures were conducted in compliance protocols approved by the Third
Military Medical University Ethics Committee, and written informed consent was received from all participants. Details of all probands are presented in Supplemental Tables 2 and 3 .
Bioinfor matics and statistical analysis 
